Anand Kiran Parikh, President and CEO of Faeth Therapeutics, Inc. (NASDAQ:FTH), filed a Form 4 on November 3, 2026, disclosing a gift of 100,000 shares of common stock to the AKP Irrevocable Trust on October 30, 2026.
Key Highlights
- Transaction date: October 30, 2026, with 100,000 shares of Faeth Therapeutics common stock transferred via gift (transaction code G) at $0 price.
- Recipient: The shares were gifted to the AKP Irrevocable Trust, established for the benefit of Parikh's immediate family members.
- Direct holdings after transaction: Parikh directly holds 717,699 shares of common stock following the reported transaction.
- Indirect holdings after transaction: 100,000 shares are held indirectly through the AKP Irrevocable Trust.
- Beneficial ownership disclaimer: According to the filing, Parikh "disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein."
- Trustee and advisor roles: Preservation Trust Company serves as trustee, and Parikh serves as investment advisor with authority to direct the trustee on investment of trust assets.
Parikh's Gift Transaction and Trust Structure at Faeth Therapeutics
According to the Form 4 filed with the SEC on November 3, 2026, Anand Kiran Parikh, who serves as both a Director and President and CEO of Faeth Therapeutics, Inc., transferred 100,000 shares of the company's common stock as a gift on October 30, 2026. The transaction was coded "G" and carried a price of $0, indicating no monetary consideration exchanged hands. The filing identifies the recipient as the AKP Irrevocable Trust, created for the benefit of Parikh's immediate family members.
Following the transaction, the filing reports that Parikh directly owns 717,699 shares of Faeth Therapeutics common stock. An additional 100,000 shares are held indirectly through the AKP Irrevocable Trust. The filing notes that Preservation Trust Company serves as the trustee of the AKP Irrevocable Trust, while Parikh retains the role of investment advisor, granting him authority to direct the trustee on matters related to the investment of trust assets.
The filing includes a disclaimer, stating that Parikh "disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein," and specifies that the report "shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose." The Form 4 was signed by Josiah Craver as Attorney-in-Fact on November 3, 2026.
What Was Disclosed
Faeth Therapeutics President and CEO Anand Kiran Parikh disclosed a gift of 100,000 common shares to the AKP Irrevocable Trust on October 30, 2026, at $0 consideration. After the transaction, he directly holds 717,699 shares and indirectly holds 100,000 shares through the trust.



Please wait processing your request...